Dr Hyam Levitsky | Executive Vice President and Chief Scientific Officer
Juno Therapeutics

Dr Hyam Levitsky, Executive Vice President and Chief Scientific Officer, Juno Therapeutics

Hyam Levitsky, M.D.
EVP, Chief Scientific Officer
Hyam (“Hy”) Levitsky is Executive Vice President, Chief Scientific Officer for Juno Therapeutics.  Prior to joining Juno in May 2015, Dr. Levitsky held the position of Head of Cancer Immunology Experimental Medicine at Roche Pharma Research and Development in Basel, Switzerland.  Prior to that, Levitsky served as a Professor of Oncology, Medicine and Urology at The Johns Hopkins University School of Medicine, and was also an active staff member in Oncology and Medicine at The Johns Hopkins Hospital. Dr. Levitsky received a B.S.  from the University of Pennsylvania School of Engineering and Applied Science and an M.D. from The Johns Hopkins School of Medicine and did his internship and residency in internal medicine on the Osler Medical Service at Johns Hopkins Hospital, rising to become Assistant Chief of Service. He trained in Medical Oncology as a Senior Clinical Fellow at Johns Hopkins Oncology Center, became Assistant Professor of Oncology in 1991, rising to full Professor in 2001, and taught in the School of Medicine until 2011. His areas of expertise include Oncology, Immunology, Hematologic Malignances / Bone Marrow Transplantation (serving as Scientific Director of the George Santos Bone Marrow Transplant Program), Cellular and Molecular Medicine, and Pathobiology.  Dr. Levitsky is also a founding Executive Committee member of the Cancer Immunotherapy Consortium of the Cancer Research Institute.  He was a Stohlman Scholar of the Leukemia and Lymphoma Society of America (LLS) and a member of the American Society for Clinical Investigation (ASCI).  He is also an active member of the American Association of Cancer Research, the American Society of Hematology, and is one of a select group of immunologists serving on review panels for both the LLS SCOR program and the Cancer Prevention and Research Institute of Texas. He was a founding member of MIATA (Minimal Information About T cell Assays), advises the FDA on cancer immunotherapy issues and serves on the External Scientific Advisory Board of the Pasteur Institute’s Center for Human Immunology, has consulted on a number of industry scientific advisory boards and contributes and provides editorial support to several prestigious cancer, immunology, scientific and medical publications.  Dr. Levitsky holds several patents.


DC Co-conference Day 2 April 4 @ 09:40

Panel Discussion: challenges to enhancing the therapeutic effectiveness of immune checkpoint antagonists with checkpoint agonists and inhibitors of immuno-metabolic pathways

  • Activating the antitumor immune T cell response through agonistic targets such as CD137 and OX40
  • Understanding the pathways used to create immune suppression and techniques to slow down immune suppression
  • What makes t-cell agonists so hard to work with vs checkpoint inhibitors?

DC Co-conference Day 3 April 5 @ 09:10

Panel: Engineering CAR-T & TCR cells for cancer therapy

  • How can you additionally modify T-cells beyond the T cell receptor/ the CAR to behave in a more controlled and/or potent fashion?
  • The challenge of keeping the manufacturing process simple, whilst maintaining the effectiveness of the product
  • The use of molecular imaging to track CAR T cells: Where do they go in the body? Do they accumulate in the tumor?
  • Mitigating side effects: controlling neurotoxicity etc.
  • Biomarkers – Identifying patients that will respond to treatment
  • Combination strategies

back to speakers